山河药辅(300452) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥140,712,067.80, representing a 16.11% increase year-over-year, while the year-to-date revenue was ¥446,238,820.02, up 17.77% compared to the same period last year [3] - Net profit attributable to shareholders for Q3 2021 was ¥19,276,546.61, a 5.28% increase year-over-year, and the year-to-date net profit was ¥72,541,670.80, reflecting a 6.11% growth [3] - The net profit after deducting non-recurring gains and losses for Q3 2021 was ¥15,754,255.48, down 2.83% year-over-year, while the year-to-date figure was ¥63,960,742.23, up 4.55% [3] - Total operating revenue for the third quarter reached CNY 446,238,820.02, an increase from CNY 378,905,903.21 in the previous period [25] - Net profit for the period was CNY 70,859,435.00, compared to CNY 68,658,514.61 in the same period last year, reflecting a growth of approximately 3.2% [26] - The total comprehensive income attributable to the parent company was CNY 72,541,670.80, an increase from CNY 68,366,538.27 in the previous period, reflecting a growth of approximately 3.2% [27] - Basic and diluted earnings per share both increased to CNY 0.40 from CNY 0.38, representing a rise of 5.3% [27] Cash Flow and Investments - The company's cash flow from operating activities for the year-to-date period increased by 137.68% to ¥37,398,682.03 [3] - Cash flow from operating activities generated a net cash inflow of CNY 37,398,682.03, compared to CNY 15,734,624.94 in the previous period, indicating a significant increase of 137.5% [30] - The net cash flow from investing activities for the year-to-date period was -¥13,309,900, an increase of 67.24% compared to the previous year [12] - Total cash inflow from investment activities was CNY 231,602,572.86, down from CNY 298,392,792.65, a decrease of approximately 22.3% [30] - Cash outflow from investment activities totaled CNY 244,912,451.34, compared to CNY 339,018,255.42 in the previous period, showing a reduction of about 27.8% [30] - The net cash flow from financing activities was -CNY 55,983,425.39, worsening from -CNY 14,135,960.23 in the previous period [31] - The ending balance of cash and cash equivalents was CNY 63,709,279.69, an increase from CNY 49,823,686.76, reflecting a growth of 28.0% [31] - The company reported cash received from the sale of goods and services amounting to CNY 369,585,368.55, compared to CNY 321,801,711.02 in the previous period, marking an increase of approximately 14.8% [28] Assets and Liabilities - Total assets at the end of the reporting period were ¥903,917,325.51, a slight increase of 0.34% from the end of the previous year [4] - The company's total assets increased to CNY 903,917,325.51 from CNY 900,871,586.44, showing a slight growth [23] - Current liabilities decreased to CNY 186,865,796.51 from CNY 217,553,295.34, indicating improved liquidity [22] - The total liabilities decreased to CNY 219,989,265.01 from CNY 245,696,995.30, reflecting a reduction in debt levels [22] - The company's equity attributable to shareholders rose to CNY 615,759,922.51 from CNY 585,208,911.21, indicating a strengthening financial position [23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,820 [14] - The largest shareholder, Yin Zhenglong, holds 26.88% of the shares, totaling 48,505,734 shares [14] - The second-largest shareholder, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., holds 11.19% with 20,195,430 shares [15] - The total number of restricted shares at the end of the period is 39,754,801, with 470,586 shares newly restricted [16] - The company has a total of 39,284,215 restricted shares at the beginning of the period, with no shares released during this period [18] Expenses and Costs - The company's management expenses for the year-to-date period rose by 36.83% to ¥21,643,200, mainly due to increased stock incentive expenses [11] - Total operating costs amounted to CNY 374,918,444.79, up from CNY 307,775,827.22 year-on-year [25] - Payments to employees increased to CNY 58,088,612.64 from CNY 45,930,513.30, representing a rise of 26.5% [30] - Research and development expenses increased to CNY 16,381,375.50 from CNY 13,051,760.34, highlighting a focus on innovation [25] Market and Strategic Focus - The company continues to focus on "comprehensive upgrading and replacing imports," adjusting product prices and expanding market efforts despite rising raw material costs [7] - The company has not disclosed any new product developments or market expansion strategies in the current report [19] - There is no information regarding mergers or acquisitions in the latest financial report [19] - The company has not provided future performance guidance or outlook in the current report [19] Other Financial Metrics - The company reported a profit before tax of CNY 81,814,013.96, compared to CNY 79,379,465.26 in the previous year, showing a positive trend in profitability [26] - The company reported a significant increase in fair value changes of financial assets, with a year-to-date figure of ¥786,300, up 904.85% year-over-year [11] - The company's cash and cash equivalents as of September 30, 2021, amount to ¥85,453,960.78, down from ¥109,320,903.74 at the end of 2020 [20] - Accounts receivable increased to ¥87,098,518.51 from ¥43,658,450.97 year-over-year [20] - Inventory levels rose to CNY 59,400,808.21 from CNY 48,855,937.68, suggesting increased production or stockpiling [21]